Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)

Artigo Revisado por pares

Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)

2016; Elsevier BV; Volume: 40; Issue: 5 Linguagem: Inglês

10.1016/j.jcjd.2016.08.116

ISSN

2352-3840

Autores

Robin Conway, Helena W. Rodbard, Ildiko Lingvay, John H. Reed, Raymond Dela Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei-Ling Chu, Nelun Wijayasinghe, Paul Norwood,

Tópico(s)

Diabetes Management and Research

Resumo

This study evaluated efficacy and safety of subcutaneous semaglutide (0.5 and 1.0 mg) vs. placebo in subjects with type 2 diabetes (T2D) treated with basal insulin±metformin.

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)